Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Longboard Pharmaceuticals Inc (NQ: LBPH )

35.54 +0.44 (+1.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Longboard Pharmaceuticals Inc

< Previous 1 2 Next >
Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on October 11, 2023
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Participate in Three Upcoming Investor Conferences
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Completes Enrollment of Phase 1b/2a PACIFIC Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Present at Upcoming Investor Conferences
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Participate in Fireside Chat with Cantor on Friday, June 30, 2023
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Reports Full Year 2022 Financial Results and Key Corporate Initiatives
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Report Full Year 2022 Financial Results and Key Corporate Initiatives on March 2, 2023
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock
From Longboard Pharmaceuticals
Via Business Wire
Longboard Pharmaceuticals Announces Pricing of Public Offering of Common Stock
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Positive Topline Data from a Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics and Pharmacodynamics of LP352 in Healthy Volunteers
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Present at Guggenheim’s Healthcare Talks 4th Annual Immunology and Neurology Day
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2022 Financial Results
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Participate in the Cantor Neurology & Psychiatry Conference
From Longboard Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.